Drug Profile
Vantox
Latest Information Update: 07 Feb 2017
Price :
$50
*
At a glance
- Originator Vyrex Corporation
- Class Antiasthmatics
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Bronchitis; Cystic fibrosis; Emphysema; Respiratory distress syndrome; Respiratory tract disorders
Most Recent Events
- 06 Feb 2017 Discontinued - Preclinical for Asthma in USA (Inhalation)
- 06 Feb 2017 Discontinued - Preclinical for Bronchitis in USA (Inhalation)
- 06 Feb 2017 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)